Fibroblast growth factor 23 concentrations in humoral hypercalcemia of malignancy and hyperparathyroidism

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Objective: To determine whether fibroblast growth factor 23 (FGF 23) concentrations are increased in the serum of patients with humoral hypercalcemia of malignancy and in those with hyperparathyroidism. Patients and Methods: Serum samples from patients with hypercalcemia and documented elevations of parathyroid hormone-related protein or parathyroid hormone levels were examined for FGF 23 concentrations. Specimens from healthy age-matched controls were evaluated to establish a reference range for FGF 23. Results: Mean ± SEM concentrations of FGF 23 were elevated in the 7 patients with humoral hypercalcemia of malignancy (385±134 relative unit [RU]/mL) compared with 11 healthy controls (43.9±5.8 RU/mL; P=.005). In the 11 patients with hyperparathyroidism, FGF 23 concentrations were increased (mean ± SEM 86.6±22.8 RU/mL), but the increases were not statistically significant. The increases in FGF 23 in these disorders did not correlate with changes in serum phosphate or 1α,25-dihydroxyvitamin D levels. Conclusion: Levels of FGF 23 are elevated in patients with tumors associated with humoral hypercalcemia of malignancy. The precise cause of such elevations requires further investigation.

Original languageEnglish (US)
Pages (from-to)826-829
Number of pages4
JournalMayo Clinic Proceedings
Volume78
Issue number7
StatePublished - Jul 1 2003

Fingerprint

Hyperparathyroidism
Serum
Parathyroid Hormone-Related Protein
Hypercalcemia
Humoral Hypercalcemia Of Malignancy
fibroblast growth factor 23
Parathyroid Hormone
Reference Values
Phosphates
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{7b01c5bc06c043489599ee44ee34cb87,
title = "Fibroblast growth factor 23 concentrations in humoral hypercalcemia of malignancy and hyperparathyroidism",
abstract = "Objective: To determine whether fibroblast growth factor 23 (FGF 23) concentrations are increased in the serum of patients with humoral hypercalcemia of malignancy and in those with hyperparathyroidism. Patients and Methods: Serum samples from patients with hypercalcemia and documented elevations of parathyroid hormone-related protein or parathyroid hormone levels were examined for FGF 23 concentrations. Specimens from healthy age-matched controls were evaluated to establish a reference range for FGF 23. Results: Mean ± SEM concentrations of FGF 23 were elevated in the 7 patients with humoral hypercalcemia of malignancy (385±134 relative unit [RU]/mL) compared with 11 healthy controls (43.9±5.8 RU/mL; P=.005). In the 11 patients with hyperparathyroidism, FGF 23 concentrations were increased (mean ± SEM 86.6±22.8 RU/mL), but the increases were not statistically significant. The increases in FGF 23 in these disorders did not correlate with changes in serum phosphate or 1α,25-dihydroxyvitamin D levels. Conclusion: Levels of FGF 23 are elevated in patients with tumors associated with humoral hypercalcemia of malignancy. The precise cause of such elevations requires further investigation.",
author = "Singh, {Ravinder Jit} and Rajiv Kumar",
year = "2003",
month = "7",
day = "1",
language = "English (US)",
volume = "78",
pages = "826--829",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "7",

}

TY - JOUR

T1 - Fibroblast growth factor 23 concentrations in humoral hypercalcemia of malignancy and hyperparathyroidism

AU - Singh, Ravinder Jit

AU - Kumar, Rajiv

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Objective: To determine whether fibroblast growth factor 23 (FGF 23) concentrations are increased in the serum of patients with humoral hypercalcemia of malignancy and in those with hyperparathyroidism. Patients and Methods: Serum samples from patients with hypercalcemia and documented elevations of parathyroid hormone-related protein or parathyroid hormone levels were examined for FGF 23 concentrations. Specimens from healthy age-matched controls were evaluated to establish a reference range for FGF 23. Results: Mean ± SEM concentrations of FGF 23 were elevated in the 7 patients with humoral hypercalcemia of malignancy (385±134 relative unit [RU]/mL) compared with 11 healthy controls (43.9±5.8 RU/mL; P=.005). In the 11 patients with hyperparathyroidism, FGF 23 concentrations were increased (mean ± SEM 86.6±22.8 RU/mL), but the increases were not statistically significant. The increases in FGF 23 in these disorders did not correlate with changes in serum phosphate or 1α,25-dihydroxyvitamin D levels. Conclusion: Levels of FGF 23 are elevated in patients with tumors associated with humoral hypercalcemia of malignancy. The precise cause of such elevations requires further investigation.

AB - Objective: To determine whether fibroblast growth factor 23 (FGF 23) concentrations are increased in the serum of patients with humoral hypercalcemia of malignancy and in those with hyperparathyroidism. Patients and Methods: Serum samples from patients with hypercalcemia and documented elevations of parathyroid hormone-related protein or parathyroid hormone levels were examined for FGF 23 concentrations. Specimens from healthy age-matched controls were evaluated to establish a reference range for FGF 23. Results: Mean ± SEM concentrations of FGF 23 were elevated in the 7 patients with humoral hypercalcemia of malignancy (385±134 relative unit [RU]/mL) compared with 11 healthy controls (43.9±5.8 RU/mL; P=.005). In the 11 patients with hyperparathyroidism, FGF 23 concentrations were increased (mean ± SEM 86.6±22.8 RU/mL), but the increases were not statistically significant. The increases in FGF 23 in these disorders did not correlate with changes in serum phosphate or 1α,25-dihydroxyvitamin D levels. Conclusion: Levels of FGF 23 are elevated in patients with tumors associated with humoral hypercalcemia of malignancy. The precise cause of such elevations requires further investigation.

UR - http://www.scopus.com/inward/record.url?scp=0037972518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037972518&partnerID=8YFLogxK

M3 - Article

C2 - 12839077

AN - SCOPUS:0037972518

VL - 78

SP - 826

EP - 829

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 7

ER -